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Abstract
Infant formulas are the only suitable substitute for humanmilk. The most common infant formulas are standard formulas based on
cow’s milk. In addition, there are formulas for infants showing signs and symptoms of intolerance and for clinical conditions such
as allergy, prematurity, and gastrointestinal diseases. A comprehensive review of the literature was made to review the composition
of standard and specialized infant formulas and analyze indications for use, real or presumed nutrition differences and properties,
and impact on infant growth. A brief consideration on costs is outlined for each formula. Over the past few years, industrial
production and advertising of infant formulas have increased. Human milk still remains the most complete source of nutrition for
infants and should be continued according to the current recommendations. Few differences exist between infant formulas, both
for the nutrition action and the macronutrient/micronutrient composition. Specialized infant formulas have limited indications for
use and high costs. The role of the pediatrician is crucial in the management of infant nutrition, promotion of breastfeeding, and
prescribing of specialized formulas only in specific clinical conditions. (Nutr Clin Pract. 2019;00:1–9)
Keywords
enteral nutrition; human milk; infant; infant formula; infant nutrition
Introduction
Human milk is the best source of nutrition for term and
preterm infants. It is unmatched and adapts over time
to meet the changing nutrition needs for optimal growth
and development of the infant.1 There seems to exist a
relationship between maternal diet and human milk nu-
trition composition, but it is still an open issue.2 The
World Health Organization (WHO) established that the
ideal feeding pattern for healthy term infants is exclusive
breastfeeding for the first 6 months of life and breastfeeding
with complementary foods for up to 2 years of age or
beyond.3,4 Nonetheless, breastfeeding prevalence remains
low in the WHO European region: in 2006–2012, only an
estimated 25% of infants were exclusively breastfed for
the first 6 months.5,6 Infant formulas are substitutes for
breast milk. They are mainly categorized into standard and
specialized formulas. The most common infant formula is
standard formula based on cow’s milk.7 Specialized infant
formula (SIF), or “formula for special medical purposes
intended for infants,” is designed to satisfy the nutrition
requirements of infants with specific medical conditions, in-
cluding prematurity; allergy; or gastrointestinal, metabolic,
or renal diseases.7 In the last few years, SIF sales have
increased significantly.8 In 2003 in Italy, the soy formula
consumption rate among 4602 infants was 34%, hydrolyzed
protein formula 21.1%, other animal milks 8.3%, and amino
acid mixtures 13%.9 Optimal nutrition is crucial to support
growth and development in infancy and can impact later
health.10 Health outcomes differ substantially for infants
who formula feed compared with those who breastfeed
(Table 1).11 Vitamins and minerals, as well as bioactive
ingredients, including nucleotides, long-chain polyunsatu-
rated fatty acids, prebiotics, and probiotics, impact health
and health outcomes. The aims of this non-systematic
review were to point out the indications for use, defini-
tions, and compositions of standard and specialized infant
formulas. A brief consideration on costs is outlined for
each formula. Articles published in English from 1998 up
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Table 1. Human Milk Factors That Reduce Risk of Poor Health Outcomes.
Health Outcomes Types Low-Risk Associated Factors and Compounds
Infectious morbidity Otitis media, lower respiratory tract
infections, gastrointestinal infections
Specific and innate immune factors, such as plasma cells,
immunoglobulins, oligosaccharides, glycoproteins,
glycosaminoglycans; human milk fats
Metabolic diseases Obesity, type 2 diabetes, high blood
pressure, cholesterols
Long-chain polyunsaturated fatty acids (arachidonic acid,
eicosapentaenoic acid), ghrelin, leptin; adipokines; protein
content; self-regulation of intake by the infant
Neurodevelopment Cognitive development and visual acuity
impairment
Long-chain polyunsaturated fatty acids (docosahexaenoic acid,
arachidonic acid, eicosapentaenoic acid); nucleotides
Atopic conditions Asthma, atopic dermatitis Specific and innate immune factors, such as oligosaccharides,
cytokines, and immunoglobulins
Others Type 1 diabetes; leukemia Cow’s milk antigen, islet-cell antibodies; specific and innate
immune protective factors against early viral infections
involved in leukemia pathogenesis
to April 2018 were identified from the Pubmed/Medline
(http://www.ncbi.nlm.nih.gov/pubmed/) database using the
following main search terms: “infant formula,” “standard
milk formula,” and “specialized milk formula.” Interven-
tion trials, reviews, guidelines, meta-analyses, and reference
lists of these studies were considered.A systematic approach
was not considered for this review because of the limited
number of published studies on this topic.
Standard Formulas
Standard infant formula is “a foodwhich purports to be or is
represented for special dietary use solely as a food for infants
by reason of its simulation of human milk or its suitability
as a complete or partial substitute for human milk.”12
Standard infant formula is only for use by healthy infants
without unusual medical or dietary problems. In 2005, the
European Society for Pediatric Gastroenterology, Hepa-
tology and Nutrition (ESPGHAN) provided proposals on
compositional requirements and nutrient levels in infant
formulas.13 Infant formula shall contain per 100 mL not
<60 kcal (250 kJ) and not>70 kcal (295 kJ) of energy when
mixed to standard dilution (20 kcal/30 mL), and it shall
contain per 100 kcal the nutrients, with minimum andmaxi-
mum levels where applicable.13 The reduced bioavailability
of nutrients compared with human milk is compensated by
the addition of other ingredients. Nonetheless, the benefit
of the addition should be demonstrated, since the mere
presence of a substance in human milk by itself does
not justify its addition to formula.13 In the United States,
the U.S. Food and Drug Administration states that the
addition of further nutrition components to infant formula
should be “generally recognized as safe.”14 The Committee
on the Evaluation of the Addition of Ingredients New
to Infant Formula has recommended that “manufacturers
must demonstrate that the formula containing the new
ingredient is capable of sustaining physical growth and
development over 120 days when formula is likely to be the
sole source of infant nutrition.”14
The most commonly used infant formula is a standard
term infant formula based on cow’s milk.15 These infant
formulas have whey:casein ratios of 60:40, a protein content
of 2–2.5 g/100 mL, and a protein/energy ratio of <3 g/100
kcal. Unmodified cow’s milk contains up to 55%–80%
higher levels of protein compared with human milk,16,17
so it must be skimmed and diluted to be a suitable basis
for infant formula. The “early protein hypothesis” suggests
that a dietary protein supply to infants in excess of their
metabolic requirements will lead to increased plasma and
tissue concentrations of insulin-releasing amino acids and
an enhanced secretion of insulin and insulin-like growth
factor-1, which in turn will enhance early weight gain,
adipogenic activity, and long- term obesity risk.18-20 Human
milk is the gold standard for infant feeding, and so infant
formula manufacturers modify cow’s milk to be more like
human milk. Cow’s milk–based infant formula contains
added antibodies, nucleotides, long-chain polyunsaturated
fatty acids, prebiotic oligosaccharides, probiotic bacteria,
vitamins, minerals, and some bioactive peptides.7 Among
amino acids, only L-forms may be added, while D-forms are
removed, as D-lactic acidosis may occur. All contain iron
for iron-deficiency anemia prevention.21 Docosahexaenoic
acid (DHA) and arachidonic acid (ARA) are added. DHA
and ARA are important for regulating growth, inflamma-
tory responses, immune function, vision, and motor and
cognitive development in infants.13 Their average calorie
concentration is 0.64–0.67 calories/mL.7 Some subcate-
gories of standard term infant formula based on cow’s
milk are organic and “for breastfeeding supplementation.”7
Standard formulas must meet all of the infant formula
guidelines and support normal growth. They are suitable
as human milk substitutes. Standard infant formulas are
available in 3 forms: the powder form, which must be mixed
with water before feeding and is the least expensive; the
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concentrated liquid form, which must be mixed with water;
and the ready-to-feed form, which requires no mixing and
is the most expensive.7 The cost of the standard powdered
infant formulas ranges between $0.13 and $0.28 for 100mL.
Specialized Infant Formulas
SIF can be defined as “a formula in liquid or powder form,
as a substitute for breastmilk or infant formula, specially
manufactured to satisfy the special nutritional requirements
of newborns/infants with specific disorders, diseases or
medical conditions.”22 Hungrier baby and goodnight for-
mulas have been included but cannot be strictly considered
SIFs, since they are intended for conditions that may be just
a perceived problem. A recent cohort study group analyzing
weight and height of 1349 formula-fed infants from birth to
4 months found that no significant relationship between an
infant’s growth and the specific type of specialized formula
exists.23 The characteristics of the main SIFs are reported in
Table 2.
Infant Formulas Marketed for “Hungrier
Babies”
Infant formulas for “hungrier babies” are predominantly
casein based, with a whey:casein ratio of 20:80. For in-
fants, casein is harder to digest, resulting in slower gastric
emptying and likely greater satiety. Otherwise, the nutrition
composition of these infant formulas is not so different
from that of standard ones, since the slightly higher car-
bohydrate and protein content is offset by a slightly lower
fat content, which maintains the total energy content at
recommended levels.24 This type of SIF has been designed
as an alternative for bottle-fed infants with a “perceived”
greater appetite, when it is too early (prior to 16 weeks
of life) to introduce infants to solid foods.25,26 The only
randomized trial investigating the effect of introducing solid
foods at 3–4 vs 6 months in 147 predominantly formula-
fed infants found no effect of the intervention on growth,
body composition, and energy or nutrient intake up to 12
months of age.27 Nonetheless, early introduction of solid
foods has recently been associated with greater probability
of later obesity in formula-fed infants,28 and this formula
may satisfy the infant so that solids can be delayed until
appropriate. In conclusion, infant formulas designed for
“hungrier babies” are suitable from birth, but the advice
of pediatricians should be asked for first. They are only
available in Europe. The costs are higher than standard
formulas (about $0.52 per 100 mL).
Goodnight Milks
The main feature of goodnight milks is the presence of
added constituents making them thicker than standard for-
mulas: the addition of rice starch or potato flakes increase
viscosity and “satisfaction”for infants. A reduction in the fat
supply keeps the total energy content within regulations. No
scientific evidences exist regarding the use of these formulas
and their usefulness in promoting sleep.24 Health benefits
and growth outcomes have not been widely investigated yet.
Inappropriate use may undermine breastfeeding and cause
the development of nursing bottle caries. Supporting data
are lacking. In conclusion, goodnight milks are suitable
from 6 months of life, but a preliminary assessment by the
pediatrician is advisable. They are only available in Europe
and are some of the most expensive commonly available
infant formulas (about $2.18 per 100 mL).
Growing-Up and Toddler Milks
Growing-up and toddler milks are an alternative, or a
complement, to whole cow’s milk for children from about
1 year of age, although some growing-up milks are suitable
from 10 months of age.24 Milks for toddlers aged 2–3 years
and for young children have recently been introduced on
the market. In comparison to cow’s milk and infant and
follow-on formula, these milks have higher concentrations
of vitamins A and D, iron, and zinc, and are poorer in
calcium and protein. Additionally, growing-up and toddler
milks have an almost double content of sugar per 100 mL
than cow’s milk. Some of the main brands of these products
contain vanilla flavoring. Growing-up milks are suitable for
toddlers, since they should receive the majority of their
nutrients from the other foods in the diet. The European
Food Safety Authority has stated that “no unique role
of young-child formulas with respect to the provision of
critical nutrients in the diet of infants and young children
living in Europe can be identified, so that these milks
cannot be considered as a necessity to satisfy the nutritional
requirements of young children when compared with other
foods that may be included in the normal diet of young
children.”29 No data currently exist on their specific clinical
indications and impact on infant growth and development.
Growing-up milks represent the fastest developing sector
of the infant formula market; they are significantly more
expensive than cow’s milk (at least 3 times).24
Formulas for Specific Symptoms
Infant colic, reflux, and perceived gastrointestinal concerns
have led to the creation and marketing of a category of
specific formulas for term infants.15,30 The main modifi-
cations in these milks include partially hydrolyzed protein
with reduced lactose or lactose free and/or added probiotics
or rice starch. The average calorie concentration of these
products is 0.64–0.67 calories/mL.7 The whey:casein ratio
of these formulas is 20:80, and this could explain the
slower gastric emptying. Carbohydrates are replaced with
rice starch or precooked corn starch to increase viscosity,
which further thickens in the acidic environment inside the
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Table 2. Specialized Infant Formulas.
Types of SIF Indications
Contraindications
and Concerns
Macronutrients per
100 mL Characteristics Costa
Formulas for
“hungrier
babies”
Children <16 weeks of
life with greater
appetite
Scarce scientific
supporting
evidence
Carbohydrate 7.7 g
Fat 3.1 g
Protein 1.6 g
Protein: intact
cow’s milk
protein
Medium low
Goodnight
milks
Children >6 months of
age that need to be
settled at bedtime
Dental caries
Inappropriate use
(more often than
at bedtime)
Scarce scientific
supporting
evidence
Carbohydrate 8 g
Fat 3.5 g
Protein 1.6 g
Protein: intact cow’s
milk proteins
Added organic corn
starch, lactose,
rice and
buckwheat flakes
High
Growing-up
and toddler
milks
N/S Nutrition properties
in comparison to
cow’s milk and
other foods
Carbohydrate 8.5 g
Fat 2.6 g
Protein 1.5 g
Protein: less than
cow’s milk
formula
Double content of
sugar per 100 mL
than standard
cow’s milk
Medium high
Anti-reflux Uncomplicated
gastroesophageal reflux
disease
Prematurity Carbohydrate 6.8 g
Fat 3.5 g
Protein 1.6 g
Protein: intact cow’s
milk protein
Lactose-free or low
content
Contains rice starch
Medium low
Lactose-free
formulas
Lactose intolerance
Acute diarrhea in children
with malnourishment
or at risk of
malnutrition
Dental caries Carbohydrate 7.4 g
Fat 3.6 g
Protein 1.4 g
Glucose as the
primary
carbohydrate
Medium low
Premature
formulas
Premature and
low-birth-weight
infants (<1500 g)
Scarce supporting
evidence for
post-discharge
formulas
Carbohydrate 8.8 g
Fat 4.1 g
Protein 2.4 g
Protein: intact cow’s
milk protein
Higher calorie
concentrations
Medium high
Partially
hydrolyzed
formulas
Marketed as intolerance
formulas; not truly
hypoallergenic
Cow’s milk protein
allergy
Carbohydrate 7.3 g
Fat 3.6 g
Protein 1.5 g
Protein: cow’s milk
proteins partially
hydrolyzed in
small peptides
Medium low
Extensively
hydrolyzed
formulas
Cow’s milk/soy protein
intolerance in
bottle-fed infants
Protein maldigestion
and/or malabsorption
Low palatability Carbohydrate 7.5 g
Fat 3.4 g
Protein 1.9 g
Protein: cow’s milk
proteins further
hydrolyzed in
small peptides
Medium high
Amino
acid–based
formulas
More severe cases of
cow’s milk/soy protein
intolerance
Intolerance of extensively
hydrolyzed formulas
Protein maldigestion
and/or malabsorption
Gastrointestinal tract
impairment
Low palatability Carbohydrate 7.2 g
Fat 3.4 g
Amino acids 2.1 g
(equivalent in protein
1.8 g)
Free amino acids Medium high
Soy-based
formulas
Vegan diet
Family preference
Galactosemia
Prematurity
Colic
Constipation
Cow’s milk
protein–induced
enteropathy
Carbohydrate 7.2 g
Fat 3.6 g
Protein 1.7 g
Protein: soy
protein
isolates
All soy formulas
are lactose
free
Medium low
N/S, not specified; SIF, specialized infant formula.
aIn comparison to the cost of standard powdered infant formula for use in term infants.
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stomach. Several formulas use carob bean gum, which is
not broken down by salivary amylase and thus maintains
viscosity. Anti-reflux infant formulas have been designed
to help relieve gastroesophageal reflux and vomiting or
spitting up in formula-fed infants. These formulas may
reduce regurgitations (from 5.43 to 2.50 mean number of
regurgitations per day)31-44 and seem to allow satisfactory
growth. Nonetheless, their use in cases of uncomplicated
reflux is not supported by the ESPGHAN Committee on
Nutrition,24,45 as gastroesophageal reflux does not gener-
ally result in adverse health effects and disappears spon-
taneously by about 3 months of age.24 These formulas
are similarly priced to standard formulas (about $0.16–
$0.24 per 100 mL).
Lactose-Free Infant Formulas
Lactose is the primary disaccharide in both cow’s and
human milk. In infants, it is the primary source of the
energy necessary to support growth.7 The principal dif-
ference between lactose free and standard infant formulas
based on cow’s milk is that in the former, carbohydrate is
glucose rather than lactose. Reduced-lactose and lactose-
free formulas have been designed for lactose intolerance,
which can be due to congenital lactase deficiency (a very
rare disorder in infancy) or transient lactose deficiency.24,46
In developed countries, the use of lactose-free formula
as treatment for acute gastroenteritis has been shown to
have no clinical advantage over standard lactose-containing
formula.45 The use of these formulas for the treatment
of acute diarrhea is not supported by the ESPGHAN
Committee on Nutrition,24,45 with the exception of very
malnourished infants. In most cases of transient lactose
intolerance due to acute gastroenteritis, it is recommended
to stay on human milk or whatever formula the infant
was on previously.7 In lactose-free formula, the common
replacement carbohydrates are cariogenic.24 Lactose-free
formula may contain cow’s milk or soy protein. The ab-
sence of lactose in cow’s milk–based formula does not
adversely affect normal growth in term infants.47 In con-
clusion, lactose-free infant formulas are suitable in transi-
tory and secondary lactose intolerance and for a limited
period. The cost of this formula is about $0.21–$0.26 per
100 mL.
Premature Formulas
Premature infant formulas are energy (about 80
kcal/100 mL) and protein (up to 2.4 g/100 mL) enriched
and variably supplemented with minerals, vitamins, and
trace elements to sustain intrauterine nutrient accretion
rates. They are composed of cow’s milk protein and
contain higher amounts of calcium and phosphorus. The
protein is intact, and whey is predominant. Lactose is the
main carbohydrate source, together with some glucose
polymers, and medium-chain triglycerides are included.7
Premature infant formulas have been conceived to fulfill
the growth/development requirements of premature and
low-birth-weight infants (infants born weighing <1500 g).7
Preterm infants are usually fed with premature formulas
before hospital discharge; indeed, these formulas are
not commonly indicated for post-discharge feeding (see
below).48 These formulas are available in ready-to-feed
bottles at different caloric concentrations, generally higher
than term infant formulas.7 The cost per 100 mL of preterm
infant formulas is about $0.84–$0.93.
Post-Discharge Formulas
Post-discharge formulas are specifically designed for
preterm infants for 3–12 months post discharge from the
hospital. These are energy (about 72–74 kcal/100 mL)
and protein (about 1.8–1.9 g/100 mL) enriched and are
variably supplemented with minerals, vitamins, and trace
elements compared with standard term formulas. The
2016 Cochrane Neonatal Review Group, which reviewed
16 eligible trials with a total of 1251 infant participants,
stated that there is limited evidence that post-discharge
formulas provide any benefit over formulas for term infants,
in terms of both growth parameters (up to 12–18 months
post term) and neurodevelopmental outcomes.48 On the
contrary, premature formula, which is generally licensed
and available only for in-hospital use, seems to promote
increased weight, length, and head circumference growth
up to 12–18 months post term. In conclusion, premature
formulas are suitable from birth for premature infants who
have higher nutrition requirements than term newborn
infants; only the so-called “preterm formula” seems to
have actual benefits on short-term linear growth. The cost
per 100 mL of post-discharge infant formulas is about
$0.26–$1.13.
Partially Hydrolyzed Cow’s Milk Formulas
Partially hydrolyzed formulas (pHF) have been produced
with the aim of stimulating the induction of oral tolerance
by keeping peptides of sufficient size and immunogenicity.
pHF are all modified cow’s milk formulas based on 100%
whey protein. Some contain lactose at lower concentrations
than standard formulas, structured vegetable oils, nondi-
gestible oligosaccharides, and added starch as thickening
agent. They are not considered hypoallergenic, but they are
more easily digested by reducing transit time and gastroin-
testinal distress for infants experiencing fussing, colic, and
constipation.7,49 pHF are also defined as “comfort milks.”
Currently, there is insufficient evidence to suggest that pHF
can prevent atopic disease.24 pHF costs range from $0.20 to
$0.25 per 100 mL.
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Extensively Hydrolyzed Cow’s Milk Protein
Formulas and Amino Acid Formulas
The extensive hydrolysis of proteins is aimed at neutralizing
allergenic epitopes. Extensively hydrolyzed cow’s milk pro-
tein formulas (eHF) are further hydrolyzed in comparison
to pHF to obtain hypoallergenicity. They are recommended
for cow’smilk/soy protein intolerance and sensitivity and for
gastrointestinal or hepatobiliary disease–related significant
malabsorption.50 eHF are less palatable than standard
formulas. Costs range from $0.41 to $0.90 per 100 mL.
Amino acid formulas (AAF) are entirely composed of
free amino acids. The use of AAF is warranted in more
severe cases, such as anaphylaxis, and also in infants who
do not tolerate eHF.50-53 AAF are also suitable for diseases
like protein malabsorption, gastrointestinal tract motility
issues, short bowel syndrome, severe food allergies, and
eosinophilic gastroenteropathies.53 AAF are less palatable
and significantly more expensive than standard infant for-
mulas (about $1.18 per 100 mL).
In infancy, the prevalence of cow’s milk protein in-
tolerance is 5%–15%, while that of allergy is 2%–7.5%.7
Infants who have cow’s milk protein allergy (CMPA) or
sensitivity and are not exclusively breastfed should be given
a therapeutic formula that is clinically proven to have
reduced allergenicity, in that, with 95% confidence, it is
tolerated by 90% of infants with CMPA. Unfortunately,
only some eHFs and AAFs in Europe satisfy this principle.
An eHF should be considered as the first choice in all
cases of CMPA, except the most severe ones, since it is
cheaper than AAF andmore effective at inducing tolerance.
Several studies have demonstrated that hydrolyzed formulas
support the normal growth of healthy term infants, also
in the first months of life.54-60 The risk of having less than
the recommended daily intake of calcium and vitamin D in
children with CMPA has been shown to be lower if children
consume a cow’s milk–free infant formula.61
Infant milk formulas from non-bovine animals (goat,
ewe, mare, donkey, or camel) have been widely marketed
as substitutes for cow’s milk, but they are not nutritionally
appropriate for infants’ needs50 and could cause harm, since
they carry a high risk (up to 80%) of cross-reactivity. In
particular, sheep’s and goat’s milks have a high degree of
homology and cross-reactivity to cow’s milk,62 whereas the
risk is lower (but still present) with donkey’s and camel’s
milks.62 No robust evidence on their use in the management
of CMPA in infants and children exists.50
Soy Protein–Based Infant Formulas
Soy protein–based formula combines protein from soy
beans with water, vegetable oils (with added DHA and
ARA), glucose syrup (or corn maltodextrin, corn syrup
solids, and sucrose), amino acids (L-methionine), vitamins,
and minerals.24 It is a plant-based formula, and therefore
it is whey, casein, and lactose free.5 Soy protein–based
formulas are recommended for infants with galactosemia
and hereditary lactase deficiency and for parents who wish
to provide their children with a vegetarian diet.63 Soy-
based formulas in CMPA can be considered when eHF
is not tolerated or is rejected by the infant, even though
up to 14% of infants with CMPA will also react to soy-
based formula because of cross-reactivity.64 Multiple stu-
dies have confirmed normal growth in term infants but not
in preterm infants.46,65 Soy protein–based formula is not
recommended for preterm newborns, since less weight gain
and more osteopenia have been observed.48 These formulas
contain higher amounts of phytoestrogens than standard
formulas.66 Evidence on the negative impact of dietary soy
isoflavones on reproduction and endocrine function is not
conclusive. In conclusion, soy protein–based formulas are
suitable from birth in term infants. The cost of soy protein–
based milks is about $0.25 per 100 mL.
Rice-Based Formulas
Rice-based formulas are not recommended for toddlers
and young children. Major issues include nutrition
appropriateness to the requirements of infants and
concentration of inorganic arsenic.67 The use of rice-based
milks may increase the intake of inorganic arsenic up to
4-fold. Rice-based formulas are available on the European
market. Their efficacy in preventing and/or treating CMPA
has not been extensively studied.52
Infant Milks for Vegetarians and Vegans
More and more individuals choose a vegetarian or vegan
diet over the conventional diet, which includes animal pro-
ducts. Vegetarianism and veganism are losing their marginal
feeding position and are becoming more popular.68 Parents
can guide their children towards this type of diet from
the very first years of life, and thus infant milk has been
designed for these new tendencies. Infant formula derived
from cow’s milk are generally not suitable for vegetarians
because of the inclusion of fish oils and/or use of the animal
source of the enzyme rennet during the manufacturing pro-
cess. Although vegetarian alternatives are available, manu-
facturers usually prefer to use rennet to separate curds from
whey.24 Currently, there are no infant or follow-on formulas
available for vegans, as the vitamin D used is sourced from
sheep’s wool. The only exception is represented by a formula
based on soy protein containing a plant-based source of
vitamin D, for children from 1 year of age.24 Scientific data
on safety, suitability, and use are lacking. Their prescription
without accurate monitoring of clinical conditions may be
responsible for malnutrition and a spectrum of iron, folate,
and vitamin B12 deficiencies. These risks must be clarified
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to vegan parents to avoid such clinical evolutions in their
children.
Conclusions
Exclusive breastfeeding represents the ideal feeding pattern
for infants. For infants who cannot be breastfed, formulas
are an acceptable alternative to provide adequate nutrition.
Only a small proportion of infants truly meet the criteria to
require SIFs. Neonatologists and pediatricians need to be
knowledgeable about these criteria and provide accurate ad-
vice. Although previously it was relatively easy to know the
components of specialized formulas based on their names,
the diversified offering of formulas on the market today can
induce confusion both in parents and healthcare providers.
Substantial evidence of links between infant nutrition and
both early and later health outcomes exists. The choice of
an inadequate formula may be associated with nutrition
deficiencies, growth failure, and poor neurodevelopmental
outcomes. Pediatricians should direct families toward the
most suitable formula for their babies, based on current ev-
idence. Finally, they should identify the minority of infants
who would benefit from an SIF. Future studies investigating
infant health outcomes of each formula are warranted.
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